OKURHealthcare · BiotechnologyOKUR Stock Forecast: OnKure Therapeutics, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering OnKure Therapeutics, Inc. hold a median 12-month price target of $19 — +360.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 1 Aug 2026 — in the upper half.
OKUR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores OnKure Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (84): The share price has been relatively steady.
Value (15): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own OnKure Therapeutics, Inc. — and when they’d sell — is the membership.
OKUR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OKUR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +360.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | HC Wainwright & Co. | Maintains | Buy | $27 → $21 |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | $34 → $27 |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Mar 2025 | Oppenheimer | Maintains | Outperform | — |
| 28 Jan 2025 | Jones Trading | Initiates | Buy | — |
| 5 Dec 2024 | Leerink Partners | Initiates | Outperform | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Oct 2024 | HC Wainwright & Co. | Assumes | Buy | $40 |
| 10 Oct 2024 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OKUR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
OnKure Therapeutics, Inc. (OKUR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 62.1×
- Price / sales
- —
- Price / book
- 0.8×
- EV / EBITDA
- 0.6×
Cheaper than 12% of US stocks
Cheaper than 77% of US stocks
Cheaper than 59% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −42.7%
- Return on assets
- −25.8%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
OKUR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OKUR appears on the weeks it earns a place.
Frequently asked questions about OKUR stock
What is the OKUR stock price forecast for 2026-2027?
The 6 Wall Street analysts covering OnKure Therapeutics, Inc. have a median 12-month price target of $19, with estimates ranging from $11 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OKUR stock a buy right now?
Of the 6 analysts covering OnKure Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OnKure Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OKUR?
As at 1 Aug 2026, OnKure Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).
Will OKUR stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +360.2% from the last close, and Ticker Nerd's factor model ranks OnKure Therapeutics, Inc. 50 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OKUR stock forecast for 2030?
No analyst covering OnKure Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OKUR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $30 over the next 12 months.
How has OKUR stock performed over the past year?
OnKure Therapeutics, Inc. returned +82.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does OnKure Therapeutics, Inc. do?
OnKure Therapeutics Inc. is a biotechnology company focused on the discovery and development of novel therapies for cancer treatment.
About OnKure Therapeutics, Inc.
OnKure Therapeutics Inc. is a biotechnology company focused on the discovery and development of novel therapies for cancer treatment. The primary aim of OnKure is to advance precision oncology, targeting specific molecular characteristics of cancer to improve treatment outcomes. The company's research is central to the field of epigenetics and targeted therapies, seeking to develop drug candidates that modify gene expression patterns linked to cancer progression. These efforts are pivotal in addressing unmet needs within the oncology sector, which is continually evolving with new biological insights and technological advancements. OnKure's role in the market is significant as it contributes to the diversification and innovation of available cancer therapies, potentially offering more effective treatment options for patients. As a player in the biotechnology industry, OnKure Therapeutics engages in partnerships, collaborations, and clinical trials, striving to bring its drug candidates from the lab to the clinic and eventually to the market as viable treatment options. Its work underscores the critical importance of biotechnology companies in advancing medical science and expanding available therapeutic solutions.
CEO Dr. Nicholas A. Saccomano Ph.D. · 45 employees · United States · https://onkuretherapeutics.com